Abemaciclib

Physiological Effects of Drugs

Eli Lilly and CompanySmall moleculePhase 3Active

B

60/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 45/ 100
Competitive Position: 95/ 100

Competitive context

9 Active assets in the Physiological Effects of Drugs cohort.

Asset / Sponsor	Phase	Rating
Empagliflozin National Institute on Aging (NIA)	Phase 4	BBB
Vts-K Theresa Jacob, PhD, MPH	Phase 4	BB
Guanfacine Maimonides Medical Center	Phase 4	BB
Pioglitazone Yonsei University	Phase 4	BB
PREDNISONE TABLETS Eli Lilly and Company	Phase 3	B

View all 17 →

Same molecule, other indications

Abemaciclib is also rated in:

hormone receptor-positive breast cancerDormant

BBB

Indicative ·

72 / 100

estrogen-receptor positive breast cancerDormant

BB

Indicative ·

70 / 100

Hormone Receptor Positive TumorDormant

BB

Indicative ·

68 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.